Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
Shire PLC said Tuesday that U.S. regulators approved its attention deficit hyperactivity disorder patch Daytrana for use in adolescents age 13 to 17.
The Food and Drug Administration approved Daytrana in April 2006 for use in children age six to 12. Daytrana delivers a dose of methylphenidate -- the active ingredient in ADHD drugs like Ritalin, Concerta, and Shire's own Adderall --
through the skin. The patch is sold in strengths of 10 milligrams, 15 milligrams, 20 milligrams, and 30 milligrams, and is designed to be worn for nine hours.
Side effects of Daytrana include decreased appetite, nausea, insomnia, weight loss, dizziness, stomach pain, anorexia, and redness or rash where the patch is applied.
U.S.-listed shares of U.K.-based Shire rose $1 to close at $63.31.